北陆药业2025年前三季度实现营业收入8.73亿元 净利润同比增81.10%

Group 1 - The core viewpoint of the article highlights that Beijing Beilu Pharmaceutical Co., Ltd. reported significant growth in revenue and net profit for the first three quarters of 2025, with revenue reaching 873 million yuan, a year-on-year increase of 19.59%, and net profit attributable to shareholders amounting to 44.18 million yuan, up 81.10% [1][2] - The growth in net profit is attributed to multiple factors, including the company's ongoing efforts in standardizing products for centralized procurement and actively promoting non-procurement products and overseas market sales, which contributed to stable revenue growth [1] - The completion of the conversion of "Beilu Convertible Bonds" led to reduced interest expenses, positively impacting net profit metrics [1] Group 2 - Beilu Pharmaceutical's subsidiary, Haichang Pharmaceutical, achieved significant progress in research and registration, including the approval of iodinated contrast agents for market entry in various countries, which lays a foundation for expanding domestic and international markets [1] - The company plans to continue its dual-driven strategy of "chemical drugs + traditional Chinese medicine," focusing on both domestic and overseas markets to enhance profitability and overall competitiveness [2]